Assay development is a crucial step in the process of drug screening against pharmacological targets. This requires expertise in using a broad array of assay technologies and developing reliable and efficient screening assays. Bio-Quant has developed a wide variety of assay technologies such as :
Proliferation (Peripheral blood cells, primary cell and cell lines)
Cytotoxicity
Cytokine Release
FACS analysis
Western Blots/Immunoprecipitation
Angiogenesis
Calcium flux
Intracellular pH flux
Shape change
Multiplex assays
Chemotaxis
ELISA (human, mouse rat, swine, dog, and primate)
Cell proliferation and growth inhibition assays (tumor and endothelial cells)
Apoptosis assays (tumor and endothelial cells)
Cell cycle and apoptosis analysis using flow cytometry
Apoptosis assays (tumor and endothelial cells)
Cell cycle and apoptosis analysis using flow cytometry
Migration and invasion assays (Matrigel® and fibrin gel)
Receptor binding and activity assays (ER, PR, AR, PPAR, etc.)
ELISA, Western blots on treated animal tissue and cell lysates for enzymes,
cytokines and other protein targets Zymogels for protease activity (MMPs, etc.)
Biochemical assays for target effectiveness on treated animal tissues
Bio-Quant has also developed uHTS fluidics and CCD imaging platforms for high density (1536) micro-volume assays. The ability to develop assays using these tools speeds the screening process and increases the number of cellular targets that can be tested. Once reagents and protocols have been developed, assays must be validated prior to their use in a screen. All of Bio-Quant's screening assays are rigorously validated to assure the value of the data generated from our screens.
 top |
 back |
